L O L I T A S M O D E L S

Call Design for All Foundation Awards 2011 New page

The Foundation Design for All announces its 2011 Awards aimed at recognizing and disseminate international good practices in the fields of design for all .

can join any project or initiative, any country and sector, which has been submitted or is completed between 01/01/2010 and 01/01/2011

categories:
- non-profit entity
- public or business administration
- Private company or professional presentation

applications: until January 15, 2011.

All information , here.

Via xvdmc .

Safe Etching Onto Zinc At Home

professional Formació

Good!

If the purpose for 2011 years by the head round Design study something but do not decide, this time I propose you to take a look at the new page FP that today! Ministry of Education has opened . TodoFP . Is

still think it's something messy, and if you the dais search engine to find, for example, "Design in Asturias, you will get a Google page with hundreds of results pdf 's Xls ' s. .. but from what I researched, is very complete

To find something that interests us, we go to Educastur . and there is search with a good dose of patience information desired

is a tool to turn to so that you begin to put the long teeth. You have been given until June to think about it!

I

Wristbank Loft Or Right

Things to think about on a Sunday: good design

that consumer hayándonos exacervado season is a good time to reflect on what a good design and take it into account when implementing our procurement season. What I'm annoying with this lately of "responsible consumers" have to see ...

Difference Between Mixer & Blenders &images

Free course for unemployed: Technician Web and Graphic Design with Adobe package LABshop 18-19/12/2010

- Duration: 300 h.

- Start Date: 28/12/2010

- End Date: 04/03/2011

- Location: Gijón

- Hours: Morning and afternoon

- Registration and information : Asturnet

C / Martinez Vigil 15, Bajo, Gijon

Tel 985 264 051


Via SEA MIST

Alexix Texas Don't Like Black Men

Market

A new edition of LABshop , the flea market design that organizes quarterly LABoral take place this weekend (Saturday December 18, 1917 to 21pm and Sunday 19 December 1912 to 21 h.) Center for Art and Industrial Creation. In the blog of LABshop can find more information and a list of participants.

Wristband Right Or Left

School Oviedo Art meets

The Art School Oviedo we owe, among other things, much of the training in the design of Asturias (and high quality) and the prestigious SUBJECT Design Conference. In 225 years, from designing the school would like to congratulate and give our congratulations for their work.

Related Links:

- The web of

School

- The School Wikipedia

- News of 225 years in RTPA

I Have A White Spot On My Bottom Lip

225 years on the conference notes: "Fabric Spray" Spray-on fabric. "Dressing in the XXI century. Fashion, Science and Technology (Manel Torres, 22/11/2010, Oviedo)

After my oblong-to-the -break vacation (and have planned the following, that well we can live this design in Asturias: sun Monday, Tuesday in the sun ...), I return to Designs with this issue in due course aroused some curiosity, nothing very revealing to contribute except some tracks, taken from my tangled notes, for which you could not be there.

"Fabric Spray" Spray-on fabric. "Dressing in the XXI century. Fashion, Science and Technology , Manel Torres
(Follow the link to the post announcing the conference to put in background)

THE ORIGIN OF THE IDEA

Manel Torres, fashion designer, trained in Barcelona, \u200b\u200btook time thinking about how to speed up the slow and therefore costly process construction of garments, when, at the wedding of some friends, serpentine spray used by the guests Spray the couple reminded him of the possibility of an instantaneous tissue, like the latter, to come out of an aerosol.
From there, he patented the idea and embarked on this self-funded project, which has lasted 10 years.

WHAT IS MADE?
As its name suggests, canned material. It is a suspension textile fibers and polymers that pass through a spray becomes a fabric woven (such as web, some napkins used in catering or bags you given when you buy something in Misako).
is applied with a spray gun, in the case of large surfaces or with a spray can, for details.

HIGHLIGHTS

- rapid construction process. Instant Dry .
- Easy to use.
- Applicable on any surface (metal, glass, breasts with the hair ...) and easy to peel.
- Light .
-resistant (to some extent: they proposed to use in sportswear for the next Olympic Games, but are not sure that is enough resistant).
- Elastic . Different thicknesses
-, applying more or less. -Different colors
. -Different textures
. For now work: fleece, similar to Polar like paper, and felt; durable, the one used for T-shirts, and lace (lace). -Ability to incorporate
aromas.
- Quick repair : just repaint the damaged area.
- washable and reusable.
-can be used to mass-produce .
"Not bad for the skin.
-degradation by UV

revolutionized the world of FASHION
Manufactures greatly accelerates manufacturing process, allows instant embroidery and 3D sketches and facilitates the repair and recycling.

also opens the possibility of introduce smart technology, implemented in active tissues, nano particles or micro-encapsulated substances. As a concept, mentioned a bikini with UV protection.

Finally, Manel hopes that, in the near future, we may acquire cans produced for us our own clothes at home , which would mean a radical change in how we consume fashion.

OTHER APPLICATIONS
"Those that happen to you", for example:

- furniture, upholstery, protective covers
- Automotive : linings (roofing, seats, dashboard). Announced that we are investigating these issues because there is a car company (mystery, mystery) interested in starting to use it in production within a couple of years.
- Medicine: transdermal patches, bandages, dressings.
- Cosmetics: Cleansing wipes, patches fragrance ... He spoke of concepts like "perfume visible" and "velvety lipstick."

ECOLOGICAL ASPECTS

-refillable cans and solvents, gases green as possible
Woven comprising biodegradable polymers and recycled fiber (eg, lab coats, old broken). It has an estimated life of 4 weeks after application .*
-reusable products.

* I understand that applications that require greater durability, less Environmentally Friendly

ECONOMIC

-The liter of material costs about 1 S.
Create the collection was presented September 20, 2010 in the parade in Style Science at Imperial College London, required 3 hours and 12 liters of material. Manel

-estimated the sale price of a can for home use would be around the 10L

As a curiosity, you can see fabricate designs made in the movie Mr. Nobody (Jaco Van Dormael , 2009, with Jared Leto).

How To Work Front Camera In Nokia E71

http : / / www.adifad.org/concursos/medallas3/concurso.php?p=presentacion&id_concurso=52&idioma=cast

Come up with another serving competitions / awards

The differences or the added value of this is that the association organizes a very prestigious designers in the scene as ADI-FAD and that the issue is a very free hand, whenever Industrial Design and the other does not ask for more resources and investments that you've spent the time since the awards Thesis / Master's Degree you've done for school

CyP from the ADI-FAD Blog:

Industrial Design Association announces ADI-FAD emerging young professionals school recently to present your Final Project, Master or Postgraduate the ADI Medal Award 2011 Industrial Design . The purpose of this award is to publicly highlight the best projects at the end of the training period, with special emphasis on those who stand out for their conceptual contributions, the process of investigation they represent and / or innovative aspects to behave in the field of design.

In open-ended, the call aims to contribute to build bridges between academia and industrial and commercial world. Remember that final date for entries for the first phase ending on 15.01.2011.

The rules, prizes, dates and so on. in the specific web ADI Medal Award 2011

Luck!

Breastfeeding Husbands In Islam

Innova Journal of CAI

Asturian Club Innovation Innova has published her magazine, with a Special

Innovation and New Technology can be downloaded from this link . 8 pages PDF. to know the current state of the industry most advanced in our region.

Play Mount Blade Free

Eleven Year Follow-up of the WHI (Women's Health Initiative = Study of Women's Health Initiative) suggest that combined hormone therapy

Eleven Years Tracking the WHI (Women's Health Initiative = Study of Women's Health Initiative) suggest that combined hormone therapy increases the risk for Advanced Breast Cancer, Incidence and Mortality in

October 27, 2010

Eleven Year Follow-up of the WHI (Women's Health Initiative = Study of Women's Health Initiative) suggest that combined hormone therapy increases the risk for Advanced Breast Cancer, Incidence and Mortality in Jaime


Urdinola MD Medical Association AK9 Andes-Bogotá 326-11620 CS-Phone DCColombia 00 571 / 21523 e-mail: jaimeurdinolamd@gmail.com- blogger: http://www.urdinola.blogspot.com www.urdinolamenopausia2.blogspot.com Symposium / Luncheon on Women's Health and Menopause Medical Association Andes - Board Room - First Floor - Wednesday, October 27, 2010

A new analysis of data from the Women's Health Initiative (WHI = Initiative of Women's Health) published a few days in JAMA, suggests that women who take estrogen and progesterone have more advanced cases of breast cancer and a mortality rate slightly higher than those women not taking this hormone combination.

The report is based on an analysis of data related to monitoring for 11 years in 12 788 women participating in the WHI study who gave their consent to continue after the initial 5.6 years, from a total at the beginning of recruited 16 608 postmenopausal women. As previously shown the report, the rate of disease among women taking the hormone combination was 0.42% per year, compared with 0.34% per year among women in the placebo group. However, recent analysis shows that among women who have developed cancer de seno, 23.7 % de las mujeres en tratamiento con la terapia hormonal presentaban nódulos linfáticos, un signo de enfermedad más avanzada, comparado con 16.2 % entre las mujeres recibiendo placebo, p= 0.03.

Adicionalmente, se observaron aprox. 2.6 muertes por 10 000 mujeres por año en las mujeres que tomaron la terapia hormonal, comparadas con una tasa de 1.3 muertes por 10 000 mujeres por año en el grupo que tomó placebo, p= 0.049. Las mujeres que tomaron la terapia hormonal presentaron una tasa más alta de muerte por todas las causas de 5.1 muertes, en comparación con 3.1 muertes por 10 000 mujeres por año en el grupo placebo, p= 0.045. Esto significa 2 muertes extra en las usuarias de hormonas.

prevalent previously thought, based on some publications until 2 years ago, it was cancer that occurs in women who took hormone therapy might be more favorable and not be a problem. But what is clear from the current publication, is that breast cancer associated with hormone therapy is linked to higher risk of death. May therefore be considered very seriously and critically, if the need for hormone therapy in menopausal women exists and is fully justified its use.

editorial in the same volume of this journal, Peter Bach suggests that researchers underestimate the increase in deaths from breast cancer due to hormone therapy, because as you follow up longer term, the deleterious effect of hormone therapy appears as a major. Bach also questioned the current form to advise women on hormone therapy in relation to the lowest dose and shortest time possible, because in reality there is a gap on this and do not really know the risks of hormone therapy led to this form.

Another of the authors of this study, JoAnn E. Manson said women should not take hormone therapy, unless really necessary, to treat moderate to severe symptoms such as hot flashes night sweats and interrupted sleep, thus seriously affecting the quality of life.

In his view this new information should not necessarily frighten women under hormone treatment, as this report found only 2 cases of breast cancer death per 10 000 women per year in women treated. The data suggest that this is cumulative with the long-term use, so women should not use hormone therapy for a long time. References


- Rowan T. Chlebowski, MD, PhD, Garnet L. Anderson, PhD, Margery Gass, MD, Dorothy S. Lane, MD, Aaron K. Aragaki, MS, Lewis H. Kuller, MD, JoAnn E. Manson, MD, DrPH, Marcia L. Stefanick, PhD, Judith Ockene, MD, Gloria E. Sarto, MD, Karen C. Johnson, MD, MPH, Jean Wactawski-Wende, PhD, Peter M. Ravdin, MD, PhD, Robert Schenken, MD, Susan L. Hendrix, DO; Aleksandar Rajkovic, MD, PhD, Thomas E. Rohan, PhD, Shagufta Yasmeen, MD, Ross L. Prentice, PhD, for the WHI Investigators. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. JAMA. 2010, 304 (15) :1684-1692. doi: 10.1001/jama.2010.1500

If you have any comments, questions or concerns, you can "click" in comments and send your message. Or if you prefer, you can send your comments, questions or concerns e-mail Jaimeurdinolamd@gmail.com

Why Do You Need To Wait A Bit After Masterbation

au

Androgens in Female Sexual Dysfunction
August 25, 2010

Androgens in Female Sexual Dysfunction

Urdinola Jaime MD
Andes Medical Association - AK 9116 20 CS 326 - Bogotá DC Colombia-Phone 571 / 215 23 00 e-mail: jaimeurdinolamd@gmail.com

blogger: http://www.urdinolamenopausia2.blogspot . com

Symposium / Luncheon on Women's Health and Menopause - Association Medical Andes - Board Room - First Floor - Wednesday, August 28, 2010

The issue of Androgens in Female Sexual Dysfunction has received much attention in recent times.

The ovary continues to produce androgens after menopause, which have been attributed a role in the behavior of the female libido. Therefore, oforectomizadas women may complain of sexual dysfunction, even if they are adequately estrogenized. Women receiving estrogens not only increase their libido or the pleasure of intercourse, according to survey data available.

studies have been conducted with transdermal testosterone therapy does not, which has shown improvement in libido and sexual frequency, although the cost of supra physiological levels of testosterone. To address this question we have developed a patch that delivers physiologic amounts of testosterone (Intrinsa ® Procter & Gamble Pharmaceuticals, USA), which has not yet been approved by the FDA 1, although presented at the 2 004. The final study was published in 2 005, with 562 surgically menopausal women were recruited in 53 centers in the U.S., Canada and Australia, comparing the efficacy of the optimal dose of 300 mcg testosterone over placebo in terms of changes in sexual function (an end mixed in a variety of sexual activities, including intercourse, masturbation, etc..). Androgen levels rose and no appreciable change in estradiol or estrone. At the end of 24 weeks of the study the difference was significant, p = 0.0003. The episodes entirely satisfactory sexual activity was of 2.10 vs. 0.98 in the placebo group.

A clinical review of 40 years on the subject was published in 2 006 2 . Initial results of studies by the pharmaceutical industry showed only an improvement moderate but statistically significant improvement in libido in surgically menopausal women receiving estrogen. However, the published data are of short duration of 24 weeks, so that concerns about the safety of long-term use, the most important, have not yet been clarified. (Table 1).

Table 1. Potential Adverse Effects of Testosterone Therapy in Women (most patterns do not occur with transdermal)

Adverse Cardiovascular

Vascular function Lipid


Syndrome Polycythemia Hirsutism

metabolic virilization (deepening of voice, clitoromegaly, male pattern alopecia) Hepatotoxicity


Acne Anger and hostility
Breast Cancer? (This requires a long-term studies)
endometrial cancer (this requires a long-term studies)

If it were to approve the patch mentioned above, the recommendation would be a short-term treatment no longer than 24 weeks in women with surgical menopause receiving estrogen and those who submit simultaneously sexual dysfunction (called by some Hypoactive Sexual Desire Disorder or in earlier times in the DSM-IV 2 001, Deficiency Syndrome Women androgen). Other currently recommend the use of oral methyltestosterone tablets, which is not available in Colombia and which must take into account their potential hepatotoxicity.

sexual dysfunction has been associated with hysterectomy, 32 to 37% of women experiencing decreased sexual response, so it has preserved ovaries. Some have suggested that this is due to the absence of the cervix, because many women report that the pressure of the penis on it triggers the mechanism of sexual arousal, given that the vaginal walls are insensitive to this stimulus, but not all studies agree with this hypothesis. Age is also a factor to consider because with the advancement of the status of menopause, the sexual response.

during climacteric ovary contributes to the movement with 50% of the production of testosterone and androstenedione 30%, although many do not consider the ovary as a primary source of androgen production. Surgical menopause does produce a sudden and significant decline in androgen levels.
Nor should we forget the contraindications to this type of therapy (Table 2).

Table 2. Contraindications for Androgen Therapy in Women

Absolute Relative

Breastfeeding Pregnancy Moderate Acne Severe Acne Hirsutism Alopecia
moderate androgenic

Polycythemia Hyperlipidemia Metabolic Syndrome Breast Cancer Cancer
/ endometrial hyperplasia

psychiatric disorders can conclude from this brief review, that the decrease androgen levels is a function of age rather than menopause itself, since many women experience increased levels of androgens to reach the early seventies, if you still have your ovaries, thus not being able to be considered as poor of them. Epidemiological studies show no correlation between androgen levels and sexual dysfunction, lack aunándose this sensitive analysis in the lower range for the measurement of androgens in women. There is still a tool, instrument or questionnaire appropriate and universally accepted to assess sexual dysfunction. Although as noted, although published studies conducted over a short time now, and financed and operated by the pharmaceutical industry, demonstrate modest but significant benefits. But although in absolute sexual benefits may seem modest, it must be emphasized that these small changes can have a substantial impact on the lives of these women. The increase in satisfying sexual event just a month can improve the quality of life of a woman, and that improvement should be accepted as valuable.

Finally, a note to ponder. In Colombia there is a pharmaceutical form of a testosterone gel approved by the Invima in 2 004 only for the treatment of male hypogonadism. Globally, the use of this type of gel is also widespread in women with sexual dysfunction, and this indication is not officially approved. But keep in mind the difficulty in standardizing the dose that is desired, not to exceed the physiological levels of testosterone. This results in abuse or accidental overuse. From the point of view of medicine based on evidence and is sparse, this practice is not recommended. References

1 - Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone Patch Increases Sexual activity and desire in surgically menopausal Women with hypoactive sexual desire disorder.J Clin Endocrinol Metab. 2005, 90:5226-33.
2 - Basari S, Dobs AS. Clinical review: Controversies regarding transdermal androgen therapy in postmenopausal Women. J Clin Endocrinol Metab. 2006; 91:4743-52 .

If you have any comments, questions or concerns, you can "click" on comments and sending your message. Or if you prefer, you can send your comments, questions or concerns e-mail jaimeurdinolamd@gmail.com

Charlie To Over Walky Talky

Statin therapy increases the risk for diabetes

Statin therapy increases the risk for diabetes
May 1926, 2 010
Statin therapy increases the risk for diabetes
Urdinola Jaime MD
Medical Association de los Andes - AK 9116 20 CS 326 - Bogotá DC Colombia-Phone 571 / 215 23 00 e-mail: jaimeurdinolamd@gmail.com- blogger: http://www.urdinolamenopausia2.blogspot.com-Symposium / Luncheon on Health Women and Menopause - Andes Medical Association - Board Room - First Floor

New data from a large meta-analysis of major statin studies suggest that these medicines to lower LDL cholesterol slightly increase the risk for Diabetes mellitus develop 1. The researchers emphasize however, that should not change clinical practice in patients with cardiovascular risk moderate or high, given the low absolute risk for developing diabetes, particularly when this fact is compared with the benefit provided by statins.

Dr. David Preiss (University of Glasgow, Scotland), one of the co-investigators of the meta-analysis has shown that although diabetes had a risk of about 9%, this is not a worrying increase as suggested by other studies . He considered a "flat." The researchers' message is that patients on statin therapy should be those that are at risk for cardiovascular (CV) moderate or high into the future. In these patients there is no doubt that the protective effects in reducing heart attack and stroke (CVA) certainly outweigh the risk of developing diabetes.

Dr. Steven Nissen (Cleveland Clinic, Ohio, USA) and who was not involved in the study considered the interpretation of the data as "responsible" and you should not alter clinical practice based on these findings, as people with diabetes previously or presented for the first time this event will have the same benefits in terms of reduction in those receiving statins, which are not resistant to insulin or who had prediabetes. Whatever this effect, this does not diminish the favorable effect of statins on clinical outcomes. No doubt today for giving statins to prediabetic diabetes because they can develop a few weeks or a few months later and denied the full benefits of these drugs.

Previous studies with statins as the WOSCOPS (West of Scotland Coronary Prevention Study), the results reported a reduction in diabetes in patients treated with pravastatin, while the recent study, large and highly publicized of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin), the researchers showed significantly more patients in the group taking rosuvastatin developed diabetes as a new entity after treatment an average of 1.9 years. This was the finding that attracted attention and triggered the controversy.

Meta-analysis was performed on 13 studies with more than 1 000 patients followed identical in the 2 treatment groups and for more than a year, including 91 140 participants. During follow-up of 4 years, 4 278 individuals developed diabetes, including statins 2 226 2 052 and assigned to control therapy. Statin therapy was associated with a significant increase of 9% in the risk for diabetes incidental. As noted in the overall results, this increased risk persisted when the analysis was restricted a placebo-controlled studies as the study JUPITER 2 and study in Japanese population MEGA (Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese) were excluded from the analysis.

Overall, 174 cases of diabetes among patients treated with statins resulting in an additional case of diabetes for every 255 patients taking statins for 4 years, according to researchers. Using data from the Cholesterol Trialists' Collaboration, this compares favorably with 5.4 deaths or heart attacks to be avoided for 4 years for each patient treated with statins. This benefit is even more larger when taking into account the reduction in revascularizations and stroke in patients treated with statins.

Table 1. Association between statins and the Development of Diabetes
Statins Odds ratio (95%) General
(n = 91 140) 1.09 (1.02-1.17)
atorvastatin alone (n = 7773) 1.14 (0.89-1.46)
simvastatin alone (n = 18 815) 1.11 (0.97-1.26)
Rosuvastatin alone (n = 24 714) 1.18 (1.04-1.33)
Pravastatin (n = 33 627) 1.03 (0.90-1.19)
Lovastatin (n = 6211) 0.98 (0.70- 1.38)

Researchers found no clear differences between hydrophilic statins (pravastatin and rosuvastatin) and Lipofen (atorvastatin, simvastatin and lovastatin), although there was a statistically significant increase in those treated with rosuvastatin. According to Preiss, the risk appears to be driven by a class effect and therefore no statin may be excluded. The 18% increase in risk for diabetes in the group treated with rosuvastatin included two studies on heart failure, a population per se has a higher risk for diabetes.

Richard Karas (Tufts Medical Center, Boston, USA) also points out that a similar problem exists with niacin and there are concerns for use in patients at risk for diabetes. But consider that clinicians use these two drugs in an aggressive manner, taking into account the increased risk for cardiovascular events and should not be shy to treat patients who need lipid-modifying therapies.

These findings may apply only to patients in the studies considered in the meta-analysis, those with moderate to high cardiovascular risk, and risk / benefit is less clear in low-risk patients treated with statins. But it may be responsible in any case, add the glucose control in patients treated with statins. It is also hoped an investigation of the effects of high vs. dosis bajas de estatinas en el riesgo para desarrollar diabetes.

Referencias
1- Sattar N, Preiss D, Murray HM, Welsh P, Bucley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarelane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-42.
2- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359: 2195-207.

If you have any comments, questions or concerns, you can "click" in comments and send your message. Or if you prefer, you can send your comments, questions or concerns e-mail jaimeurdinolamd@gmail.com

Are Chikan Movies Real

News in non-hormonal treatment of menopausal symptoms

June 30, 2010 News

in non-hormonal treatment of menopausal symptoms

Jaime Urdinola MD

Medical Association Andes-AK 9116 20 CS 326 - Bogotá DC Colombia

☎ 571/2152300 e-mail: jaimeurdinolamd@gmail.com

blogger: www.urdinolamenopausia.blogspot.com - www.urdinolamenopausia2.blogspot.com

Symposium / Luncheon on Women's Health and Menopause
Andes Medical Association - Board Room - First Floor

Wednesday, June 30, 2010

Introduction

vasomotor symptoms are common in the menopausal transition period. informing up to 57% of hot flashes and 50% in postmenopausal 1. Most women (60%) are experienced for 7 years, although 15% still exist for more than 15 years 2. And traditionally have been treated effectively with hormone therapy (HT), the only therapy approved for this purpose. Obviously today, after the publication of the WHI (Women's Health Initiative) in 2 002, there is concern about possible adverse effects of HRT on the breast and uterus. For this reason, is currently being evaluated today by treatments SERM (Selective Oestrogen Receptor Modulators) through estrogen agonist or antagonist effects, alone or in combination with estrogen as is the case bazedoxifene and hormonal therapies Action on central nervous system (CNS) to the alleviation of vasomotor symptoms, such as various antidepressants and the use of gabapentin and clonidine. The dietary herbal supplements such as soy and "black cohosh" or radúnculo have shown mixed results and inconclusive in controlled clinical studies placebo. In study also finds a Chinese herbal therapy directed at β receptor, the compound MF-101.

MF-101-Selective Estrogen Receptor β
selective agonists can stimulate estrogen receptors or receptor α or β receptor inducing estrogenic effects specific tissue, thereby providing a safe alternative compared to the TH. MF-101 is derived from 22 herbs that are traditionally used in Chinese medicine for treating menopausal symptoms. Preclinical studies and one Phase II liquiritigenina made to date and chalcone isolated active compounds (found in alcazuz licorice or English) show selectivity for the estrogen receptor β without induction of proliferative events, growth of cancer cells in the breast or uterine growth stimulation 3. To confirm its safety and efficacy results are expected Phase III studies, which were planned for the year 2 009.
For those women who can not take estrogen or who choose not to use them, but persistent symptoms of moderate to severe intensity, the current options for management of vasomotor symptoms are centrally acting antidepressants, and gabapentin and clonidine.

Neuroactive agents
Most studies have been conducted in women with breast cancer or at increased risk for this problem. Apparently, increased serotonergic activity in the CNS reduces hot flashes, possibly through a fading effect of the suspension at the central level of opioid peptides or reducing noradrenergic activity. We have studied the inhibitors of serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, citalopram and mirtazapine, as well as inhibitors of norepinephrine reuptake (SSNI) such as venlafaxine and its metabolite desvenlafaxine, and gabapentin. Venlafaxine
, desvenlafaxine, paroxetine, and clonidine appear be those that produce more relief and reduction of vasomotor symptoms between 50 and 67%. The effects are apparent after 4 weeks and the answer seems to be stable up to 12 weeks. However, the extent of relief over time, the doses needed for maximum benefit and whether the impact varies according to specific medication use, are questions not yet fully clarified 4 . Concomitant use of MAO inhibitors (MAOI), thioridazine, warfarin is contraindicated with SSRIs. Adverse effects in patients treated for depression include asthenia, sweating, nausea, decreased appetite, somnolence, insomnia and dizziness. Also, can inhibit cytochrome P450 enzyme CYP2D6, which contraindicated use in patients receiving tamoxifen for breast cancer, it will reduce your metabolism up to 60% at its most active, endoxifen. The power described for the inhibition of this enzyme varies between paroxetine (the highest), fluoxetine, sertraline, citalopram and venlafaxine (the lowest). Venlafaxine


A double-masked, placebo-controlled randomized (n = 191, efficacy evaluable for 4 weeks) at doses of 37.5, 75 or 150 mg in women with a history of breast cancer or who refused to receiving HT. In the end, women with placebo showed a decrease of 27%, 37% with 37.5 mg and 61% with 75 and 150 mg, the latter being no more effective dose of 75 mg and associated with an increase in dry mucous membranes, anorexia, nausea and constipation 5 . An open study 6 continuation reported a sustained reduction in hot flashes and other randomized controlled 7 (n = 80, 12 weeks) in postmenopausal women receiving 37.5 Initial mg and 75 mg after 1 second. week for 11 weeks, found that the severity was not statistically decreased significant, but its effects on daily living were significantly improved (p = 0,001). 93% of patients in the venlafaxine group chose to continue treatment.

desvenlafaxine
metabolite of venlafaxine demonstrated in a randomized controlled trial (n = 458, postmenopausal women) at a dose of 100/150 mg / day, a significant reduction in the number of hot flashes at week 4 and 12 , up 66.6% at week 12 compared with placebo, 50.8% 8. Most adverse events were reported in the first week than with placebo, as appropriate titration of the dose appears to improve initial tolerance and decrease the adverse event reporting. Fluoxetine


Discussed in doses of 20 mg in a randomized double-masked (n = 81 for 4 weeks, tamoxifen and raloxifene permitted by previous breast cancer). The rates of hot flashes decreased 50% vs. placebo 9 and analysis were crossed vs index improved. placebo (p <0.02).


Citalopram vs
was studied. Fluoxetine (n = 150, 9 months) in a randomized controlled trial, beginning with 10 mg and increasing to 20 mg at 4 weeks and 30 mg at 6 months . There were no differences significant relief, between treatment and placebo groups, although a positive trend for the SSRI. Insomnia was significantly improved with citalopram 10 . Paroxetine


twice in a multicenter randomized controlled trial (n = 165 for 6 weeks, raloxifene, tamoxifen and vitamin E allowed), women who received paroxetine CR at doses of 12.5 and 25 mg had a reduction in 62. 2 and 64.6%, vs. a reduction of 37.8% in the placebo group 11.


Clonidine has been studied in oral and transdermal 12.13 , the oral dose of 0.1 mg / day vs. placebo (n = 194 for 8 weeks) in patients with breast cancer receiving tamoxifen, a decrease of 38% vs. 20% for placebo. Adverse effects were dry mouth, drowsiness, constipation and dizziness, which decreased by using the patch given as a dose escalation.


Gabapentin is approved as an anticonvulsant and for the treatment of postherpetic neuralgia. Serves as an agonist of γ-amino acid butíricoy is believed to affect the temperature regulation through its link a calcium channel. Randomized controlled studies suggest that its efficacy is superior to placebo. In one study (n = 59, allowing antiestrogens, clonidine or antidepressants) at a dose of 900 mg, were reduced hot flushes 54% vs. 31% with placebo (p = 0.01) 14. In another open study with higher doses of 900 mg reduced hot flashes was higher, however 50% of patients reported at least one adverse event vs. 27.6% in the placebo group. 13.3% was suspended due to drowsiness, dizziness or skin rash. In another large study, randomized controlled trial with doses of 300 and 900 mg (n = 420 patients, 371, measurable, with a history of breast cancer) 15, the index of severity of hot flashes declined 21% in week 4 and 15% at week 8 vs. placebo with 300 mg of gabapentin, and 49 and 46% respectively with a dose of 900 mg. The latter dose is significant in reducing the frequency of heat waves and their severity. It should be emphasized however, that although gabapentin appears to be effective, adverse effects are significant and longest published study has only 12 weeks.




Conclusion Venlafaxine, desvenlafaxine, paroxetine, gabapentin and clonidine as trandérmica oral and currently appear most promising agents for non-hormonal treatment for vasomotor symptoms. Awaiting results of tests on the compound MF-101, β-receptor agonist. References


1 - Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the Association Between Vasomotor Symptoms and race / ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006, 96:1226-35.
2 - Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990, 592:52-86.
3 - Stovall DW, Pinkerton JV. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women. Curr Opin Investig Drugs. 2009; 10: 365-71.

4- Pinkerton JV, Stovall DW, Kightlinger R. Advances in the treatment of menopausal symptoms. Women's Health. 2009; 5: 361-384.

5- Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000; 356: 2059-63.

6- Barton D, La VB, Loprinzi C, Novotny P, Wilwerding MB, Sloan J. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum. 2002; 29: 33-40.

7- Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005 ; 105: 161-6.

8- Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S; Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009 Mar;200: 238.e1-238.e10.

9- Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002 15; 20: 1578-83.

10- Suvanto-Luukkonen E, Koivunen R, Sundström H, Bloigu R, Karjalainen E, Häivä-Mällinen L, Tapanainen JS. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005; 12: 18-26.

11- Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003 ; 289: 2827-34.

12- Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, Pierce HI, Dragalin V, Morrow GR. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000; 132: 788-93.

13- Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland KM Jr, Burnham NL. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994; 12: 155-8. Erratum in: J Clin Oncol 1996; 14: 2411.

14- Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003; 101: 337-45.

15- Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ. Gabapentin for hot flashes in 420 Women with breast cancer: a Randomised double-blind placebo-controlled trial. Lancet. 2005, 366: 818-24.


If you have any comments, questions or concerns, you can "click" on comments and sending your message. Or if you prefer, you can send your comments, questions or concerns e-mail jaimeurdinolamd@gmail.com

Plan Wood Carving Bench Portable

Will Without the risk of coronary heart disease in women treated with hormone therapy?

Will Without the risk of coronary heart disease in women treated with therapy hormonal?
May 26, 2010
Will Without the risk of coronary heart disease in women treated with hormone therapy?
Jaime Urdinola
MD Medical Association of the Andes - AK 9116 20 CS 326 - Bogotá DC Colombia

Phone 571/215 23 00 e-mail: jaimeurdinolamd@gmail.com

blogger: http://www.urdinola.blogspot.com www.urdinolamenopausia2.blogspot.com

Symposium / Luncheon on Women's Health and Menopause Medical Association

Andes

Board Room - First Floor - Wednesday May 26 2010

A new analysis from the Women's Health Initiative (WHI = Women's Health Initiative) ha encontrado, que entre las mujeres menopáusicas recientes, la terapia hormonal (TH) con estrógeno + progesterona aumenta ligeramente el riesgo para enfermedad cardíaca coronaria (ECC) dentro de los primeros años de uso. Pero el aumento hallado no fué estadísticamente significativo 1 .
El autor principal Dr. Sengwee Darren Toh, de la Escuela Médica de Harvard y del Instituto del Cuidado del Peregrino de la ciudad de Boston en EE.UU. manifestó que el análisis se enfocó en las mujeres menopáusicas recientes “porque ellas son las que con mayor probabilidad utilizan la terapia hormonal”. Este aumento leve aunque no significativo, de alrededor del 29 % durante los First 2 years of use, disappeared after 6 years of use, and in fact, the researchers then used this period identified a cardioprotective effect of hormone therapy in this group of women. But given that today women use hormone therapy for less than 6 years, these women can not expect this cardioprotective effect is present in them.
These findings support the recommendations of the FDA (Federal Food and Drug U.S.) for women taking HRT if needed, to relieve symptoms of menopause, but their use should be made when it has been termed "the lowest dose for the shortest time possible," somewhat vague implicit in this definition.

further research: the result varies with HT according to time and proximity to menopause?

Toh explained that he and his group were tempted to review the WHI data 2 because "we wanted to bring to light and see if the effect of HT on risk changed over time and according to proximity to the time of menopause. " This was partly stimulated considering the so-called "Hypothesis of Opportunity" 3 , which suggests that the effects of HRT vary depending on when the woman starts treatment. According to this hypothesis, HT may reduce the risk for CHD among younger women who do not have advanced atherosclerotic plaque, but instead may accelerate as the ECC in older women, or those with advanced lesions . Toh and her colleagues also adjusted data from the WHI regarding adherence to treatment in their analysis, since the lack of compliance was a major problem in this study, in accordance with his explanations. Approximately 40% of women had suspended 80% of the assigned treatment medication in the sixth year. A standard approach to intention to treat, which makes no adjustment grip incomplete, can lead to misleading results.

Overall, 16 608 women in the WHI study 4 , who were randomized to receive 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone acetate (n = 8506) or placebo (n = 8 102 ), Toh and colleagues found that compared with non-use of HT, the hazard ratio for CHD for the continued use of HT was 2.36 for the first 2 years of use and 1.69 for the first 8 years. But recently menopausal women, within the first 10 years of menopause, the hazard ratio was 1.29 during the first 2 years and 0.64 during first 8 years of continuous use of HRT (n = 2782) vs. Placebo (n = 2712). Free survival curves of ECC for the continued use of TH and non-TH using crossed about 6 years of study. Toh and colleagues also combined these numbers with data from the Nurses 'Health Study (Nurses') 5 to make more robust the analysis, finding that the results did not change substantially and that the crossing of the curves survival occurs in the latter study at 3 years.

In the early years of recent menopausal women no real increased risk, but there was no cardioprotection

It confirmed the findings of WHI a few years ago, the different statistical analysis, finding that although it is possible that younger women get the benefit of HT based on the hypothesis of Opportunity, not seems to happen within the first years of use. Therefore, according to Toh and colleagues, "an expected reduction in risk of CHD should not be a consideration for the initiation of HT in younger postmenopausal women." These data suggest that there is a significantly increased risk in this group of young women, but otherwise there was not a cardioprotective effect during these early years. It also clarifies that this group of young women in the WHI study was not as large as desirable, so that did not acquire the necessary statistical power for these findings were entirely accurate. But anyway emphasizes that the group of WHI study data is best found on this topic, so that we have analyzed the most appropriate form has been possible. In addition, women in this age group currently using HRT for a short period of time. References


1 - Toh S, Hernandez-Diaz S, Logan R, Rossouw JE, Hernán MA. Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Dissappear ? Ann Intern Med. 2010; 152: 211-7.
2- Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33.
3- Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol. 2007; 166 :511-7.
4- Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators. Estrogen plus progestin and the Risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
5 - Hernán MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Manson JE, Robins JM. Analyzed Observational studies like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008, 19: 766-79.

If you have any comments, questions or concerns, you can "click" on comments and sending your message. Or if you prefer, can send comments, questions or concerns e-mail jaimeurdinolamd@gmail.com

Cost Replace Winshield Wiper Motor

Reduce Breast Cancer bisphosphonates when used to treat osteoporosis?

April 28, 2010

Reduce Breast Cancer bisphosphonates when used to treat Osteoporosis ?

Urdinola Jaime MD

Medical Association Andes CS AK 9116 20 326 Bogotá DC Colombia - Phone 571 / 215 23 00
e-mail: jaimeurdinolamd@gmail.com
blogger: http://www.urdinola.blogspot.com www.urdinolamenopausia2.blogspot.com
Symposium / Luncheon on Women's Health and Menopause Medical Association
Andes - Living Boards - First Floor
Wednesday April 28, 2010

A third study and the first to be published a have reported a reduction in the risk for breast cancer in postmenopausal women take bisphosphonates as a treatment for osteoporosis.

These findings are published in the March 2, 2010 the British Journal of Cancer, reporting a case-control analysis of about 6 000 women in the U.S. Wisconsin stadium aged <>

Polly Newcomb, the study's lead author and Director of the Cancer Prevention Program of the Center for Cancer Research Fred Hutchinson in Seattle, Washington, USA, conceptualized in a press release, this large study provides new evidence that the use of bisphosphonates is associated potentially with a reduced risk for breast cancer.

This reduction in risk for breast cancer is similar to that reported two studies that were submitted in December 2009 in Cancer Symposium Within San Antonio, Texas, USA One of the analysis dealt with 150 000 women who participated in several studies of the WHI (Women's Health Initiative), which found that the use of bisphosphonates (mainly oral alendronate) reduces the risk for breast cancer at 32 %. The other study looked at 4 575 women in a study in northern Israel for 5 years, finding a reduction of 34%.

The fact that they are similar findings in different populations of 2 continents is encouraging, although these findings should be confirmed in controlled trials.
During the symposium in San Antonio discussed the consideration to be done on possible factors called "confounders." Such as women who take bisphosphonates for osteoporosis have low bone mineral density, which is an indicator of reduced estrogen levels, which could influence the risk for breast cancer.

already published in the study, the authors emphasize that they considered important confounding factors such as body mass index and use of postmenopausal hormone therapy. In addition, analyzed the reasons were prescribed bisphosphonates, such as a fracture, the decrease in height and medical diagnosis of osteoporosis. There was some suggestion that the use of bisphosphonates was associated with a reduced breast cancer risk only among women who had reported symptoms related to bone loss, but this was not statistically significant.

these researchers conclude that these findings may reflect real benefits because of anti-tumor mechanisms of bisphosphonates.

Keep in mind, however, that the reduction in breast cancer risk was seen only in women who were not obese, not appreciating in obese women. This suggests that the inhibitory action of these drugs is related to a threshold effect or other hormonal factors growth, which is known to be important factors for exposure in breast cancer.
Obese women may have higher estrogen levels, so that the underlying hormones may influence the ability of bisphosphonates to reduce the risk for breast cancer.

I still do not know the exact mechanism by which bisphosphonates can prevent breast cancer, although these drugs have multiple actions that may be relevant, it has been shown to cause tumor apoptosis, inhibit angiogenesis and prevent tumor cell adhesion, thus affecting cell function and participate in the growth and cell death, specifically in the death of tumor or even premalignant disease.

In women with advanced breast cancer and bone metastases evident, the use of oral or intravenous bisphosphonates in addition to hormone therapy or chemotherapy, when compared with placebo or non-use of bisphosphonates reduces the risk of developing skeletal events and the rate of skeletal events, as well as increases the time to submit a skeletal event 2.
A recent large study has reported beneficial antitumor effects of nitrogenous bisphosphonates in women with breast cancer 3 . This effect was not observed with non-nitrogenous bisphosphonates such as clodronate, and both appear to be toxic for macrophages to the osteoclast.

The idea that bisphosphonates reduce breast cancer is very attractive, considering that only in the U.S. produced about 30 million prescriptions for these agents annually.

As positive conclusion to remember is that these results are suggestive of an additional benefit of the common use of bisphosphonates, in this case, the reduction in risk for breast cancer.


References 1 - Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates Treatment for osteoporosis Are Associated with Reduced Breast Cancer Risk. Br J Cancer. , 2010; 102:799-802.
2 - Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2002; (1): CD003474.
3 - Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.



If you have any comments, questions or concerns, you can "click" on comments and sending your message. Or if you prefer, you can send your comments, questions or concerns e-mail
jaimeurdinolamd@gmail.com

Why Hypothyroidism More Common In Women

Antique Lamps Rustic Lamps

The most common lamps often can not produce enough light for your living space, and should be combined with other types of lighting. In that sense, a classic and distinguished lamp floor can be a great solution, especially when you want to give your home a classic look.

antique floor lamps are versatile lighting devices that can be added anywhere in your home. Lighting are excellent choices for any living space as well, such as apartments, condominiums, houses, personal property and even office space. The old lamp is one of the most famous styles floor lamps loved by most people. Are the common choice of consumers because of its elegant views and clear light.

Different colors and types of antique lamps to choose from. One of the popular antique lamps floor lamp is bronze. It will give your classic theme room and light enough to read easily and decorative enough. Soft lighting produces light that bounces off the ceiling, which highlights the area significantly.

Although antique bronze lamp has an elegant and magnificent panorama, not expensive at all. In fact, you can easily get for under $ 100. Another good thing about antique brass lamp is that it is very easy to install and require no complicated wiring. Professional help is not needed because all you need do is connect to the available output.

Playground Wallpapaaaer

If you have an original rustic theme and is planning to install lighting equipment, you should know some great ideas for rustic lighting that can be used at home.

When you hear the word "rustic", which automatically comes to mind is the word "natural." This is due to a style that usually features rustic furniture and decor at its most natural. For example, rustic chair will have rough edges and natural finish that looks very nice and unique. Most of these pieces of rustic furniture and decor are handmade. Men and women spent countless hours perfecting their art, making the original rustic pieces. You will not find a mass production of rustic furniture and decor that makes it even more special.

These characteristics are also true for rustic lighting fixtures. They look great not only for rustic-themed rooms but also in other types of rooms. To help you choose the perfect lighting fixture for your needs, Here are some great ideas for rustic lighting.

• One of the most original ideas is lighting the candle. You can buy chandeliers from antique shops or at auctions or search online. For a more original version and rustic chandeliers can still use with horns or antlers.

• You can use wood or branches trimmed to create a rustic lamp. You must apply varnish to the wood trim or twigs first before they are set in the lamp.

• Another great idea is to use dried leaves, resistant. Go outside and collect some leaves that have fallen from a tree. Soak them in shellac and paint in different colors or a single color, depending on your preference. Paste one by one in the lampshade. This is a very inexpensive way to create a unique and rustic decor lighting.

can also create a miniature wagon wheel and apply it to the top of the screen. These are just a few options but the idea is to create your own rustic lamapras playing with the imagination.



rustic wood rustica candle chandelier wheel

The Most Big Collection Of Tech Deck Skates

Fluorescent Lamps Decorative Lamps

A light bulb is also known as an incandescent bulb. Makes use of a thin tungsten filament. Electricity as it passes through the filament is heated until it turns white. This white light is produced. Along with the light generated, the light bulb also produces a large amount of heat. This is considered a waste of energy. The attempt to harness this energy has given way to the fluorescent lamp. They are energy efficient light bulbs that use tungsten to generate light.

The fluorescent lamp uses a different method to produce light. Makes use of electrodes at both ends of a fluorescent tube. argon gas vapor and mercury inside the tube. A stream of electrons flows through the gas one electrode to another. These electrons collide to excite mercury atoms. The mercury atoms emit ultraviolet photons.

These photons hit the phosphor coating inside the fluorescent tube. The phosphor creates visible light. This makes fluorescent bulbs give you four times more than incandescent bulbs generate. A fluorescent light bulb 15 watts produces the same amount of light that a 60-watt incandescent bulb.

A fluorescent bulb generates less heat. It can produce between 50 and 100 lumens per watt. Provides a white light and consume less energy.



fluorescent mercury fluorescent phosphor tube

start lamps Decoracion

Milena Velba No Bad Images

If you've recently bought a new house or if you are looking to fix your existing home, then it is likely that you are also looking for ways to maximize their efforts when it comes to improving the decor. When it comes to interior decorating, the fact is that most people consider the larger items such as paint, carpets and furniture before smaller items. While these larger things are important and all contribute in their own way to the appearance of your home, not are the only tools you can use. In fact, there are several smaller elements that can really let you customize your space without incurring a lot of costs.

One of the least expensive and often overlooked pieces of decoration are the lamps. Prior to diminish the importance of the lights, they realize for a second how much you contribute to your lifestyle. Lamps not only allow us to live our lives when the sun goes down, can also be used to spice up our decor in your own unique way. Although most people tend to think of the lamps and utilitarian, the fact is that it is possible to buy different types lamps and lampshades beautiful. A glance through some of the most popular home and websites published several examples in which the lamps have been used with great effect to make a room feel more comfortable and welcoming.

When it comes to buying lamps and decorative screens in reality there is only one viable option - the Internet. Although you can "surf" your local home improvement, it is very likely to go away disappointed because of the lack of selection and high prices. The reason that online shopping is much better to do with the large number of specialty retailers that exist in the online market. Since most of these traders do not have to deal with large overhead costs, it may be very competitive in price side, which means you can save money.



decorative decorative decorative decorative shop find

Honda Pilot Front Wheel Noise

Have you ever seen a lamp with a glass screen and wondered what was his name? Most people probably do not even know that there is a name for that kind of light and just assume it is a fancy lamp with a glass screen, however, this is simply not el caso.

Estas lámparas de fantasía se llaman las lámparas Tiffany, que originalmente eran parte del movimiento Arte Nouveu, y se componen de una pantalla de vidrio (Tiffany) soldadas con una lámina de cobre. Fueron diseñados por primera vez en 1899 por la Tiffany Lamp Company. Originalmente, diseñó las vidrieras, que es como le ocurrió la idea para hacer lámparas. Sorprendentemente, una pieza original puede venderse por hasta ocho millones de dólares en una subasta.

Así que usted no tiene 8 millones de dólares, pero quiere comprar una lámpara de estilo Tiffany? Bueno, eso es totalmente comprensible. La buena noticia es que es posible convertir cualquier lámpara en una Tiffany lamp by simply buying and installing a screen instead of buying Tiffany lamp. There are lots of Tiffany lamp shades available for you to choose, so that may add the style of your lamp, and complement the original design.

You can buy Tiffany lamp shades that resemble the windows of a church, they are very beautiful. These are best used as decoration, as they tend to be very weak. You may see a light like yours in a fancy restaurant or bar, where little light is used to set the mood. They do a great job. They are also popular in offices where they go very well with expensive wooden furniture.

There are also more modern contemporary designs that use neutral colors and are suitable for the most elegant designs. These are not as colorful or decorated as traditional forms of tiffany lamp, but is more likely to coincide with contemporary furnishings.

Despite all these options are cheaper alternatives to the original Tiffany lamp. You can probably find a local store that sells them, but most likely find them online.



tiffany glass display screens welded copper

Other Software Like Is In Jibjab

Design Lamps Paper Lamps Hanging Lamps

The first step:

The paper Lamap are some of the best and most beautiful crafts that are sought by people around the world. Its light and pleasant colors bring nostalgic memories for many. These gears are easy to make paper. The first step is to get an idea of \u200b\u200bthe type of paper lanterns are going to design, what color will have size and shape?. Once this is decided you can get to work making paper lamp. With the open design, you can go ahead and get the materials needed to build your design.

Pre-requisites:

There are several prerequisites that must be bought or found before you start making the lamp. Objects that are needed, scissors, paper cutter, ribbon, a candle, a battery and various other items. Once these items have been assembled can start.

Instructions:

1. Take a rectangular piece of paper and fold along its length. Unfold the paper and cut a narrow strip out of it at the end. This will serve as the handle of the lamp.

2. Now fold the paper in half which is long and thin.

3. Draw a faint line on the paper in the region where it bends. This is the line that is supposed to cut the lamp.

4. Make a series of cuts on the line and make sure they are well placed. Do not cut the edges and leave at least a gap of one inch of edges.

Designs:

After completing the cut, unfold the paper and wrap the unit in a cylinder (using lateral if you want one similar to the picture). The short edges to be left alone are now glued or fastened. Once done, the narrow strip that was cut in the early stages and may be placed in the edges so that the handle is formed. Within minutes your paper lamp is complete. Can be improved in many respects, this is just the basic model of a paper lamp. There are several other types of paper lamp made of different materials used for other purposes.



craft paper instructions Japanese crafts materials

Places A Boat Diagram

The pendants are very versatile. They adapt to any place, but when you really must choose one? There are several things to consider.

First, what task you are performing this lamp? Is it to be used for reading, hobbies, etc, or just light the room? "The light will go on a table next to a chair or a sofa, next to the bed, just what is its purpose and where you put it?

Secondly, are you sure to choose a pendant lamp, because you do not have enough space for a floor lamp or table lamp? You must remember, once you install a pendant that will be fixed. You can not move one of the lights around as you can with other lights when you want to rearrange the furniture. If you decide to move the lamp hanging from the ceiling, you have to patch the hole. Remember that you may be unable to match the exact color on the ceiling or if you have tiles on the roof, you may not have another piece to the height, etc. This could become a real problem.

Third, if you choose the pendant, you will need to ensure the preparation of the roof safely.

Fourth, how high or how low is going to hang the lamp? If it is going in the middle of the room, I want it high enough to provide light throughout the room. If it is a large room, you should choose a pendant with two or three light bulbs at least it will provide enough light. If the lamp is going over a small breakfast table or a chair next to a close reading or crafts, you might want to hang lower and does not need many bulbs.

Fifthly, you have to consider the style and design of the lamp. You have to choose one that suits your decor. In addition, there are lamps hanging pan upside down and those with the bowl facing toward the ceiling, which will you choose?

Sixth, there are many advantages of having a lamp hanging from the ceiling. You do not have to move to clean under them, would only have to clean the lampshade. Another thing is that you do not have to worry about them knocking off a table or run into them and causing its collapse. Most pendants are a cable or chain.




hanging pendant pending rope chain advantages

Extigy Midi Port Windows 7

to modern life and fashion, it is natural that you need all the modern, why not go by modern lamps?. With the fast changing world, everyone wants something new and the latest in their homes either television, refrigerator, car, mobile, clothes and even in regard to the decoration of the room, which is a part of life .

When it comes to table lamps, of course, the people, especially the younger generation will love to own and care for what is best and modern.

Such lamps are very hard to find if you're going to look in your local stores, because many of these stores often have traditional lamps are not equipped with the latest, but you can find these lights in your choice easier online stores.

modern table lamp has sleek curves with it allowing them to give the effect of simplicity through simple lighting giving serenity and a sense of intrigue. The style of these lights has its own distinct look and makes it very different from the rest of the lights. Among all the modern lamps table, modern glass lamps are very popular and the most popular second Suki Tall lamps.

There are many more modern lighting and each is unique with added capacity for innovation and design, to make you feel eager to buy them all!.



modern designs curved lines design style